NCT00768326 - Efficacy of Lu 31-130 in Patients With Schizophrenia | Biotech Hunter

Enrollment

280

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions

Schizophrenia

Interventions

DRUG

Zicronapine

"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"

DRUG

Zicronapine

"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"

DRUG

Zicronapine

"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"

DRUG

Zicronapine

"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"

DRUG

Zicronapine

"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"

DRUG

Placebo

"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"

Trial Locations (1)

DE001, Munich

All Listed Sponsors

lead

H. Lundbeck A/S

INDUSTRY